Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2141851

CytRx Corporation - Product Pipeline Review - 2012

Description:

CytRx Corporation – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “CytRx Corporation - Product Pipeline Review - 2012” provides data on the CytRx Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CytRx Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from CytRx Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CytRx Corporation - Brief CytRx Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CytRx Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CytRx Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CytRx Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CytRx Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CytRx Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CytRx Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CytRx Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of CytRx Corporation; CytRx Corporation - Key Therapeutics; CytRx Corporation - Pipeline Overview and Promising Molecules; CytRx Corporation - News; CytRx Corporation - Latest Updates; CytRx Corporation - Pipeline; CytRx Corporation - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
CytRx Corporation Snapshot
CytRx Corporation Overview
Key Information
Key Facts
CytRx Corporation – Research and Development Overview
Key Therapeutic Areas
CytRx Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
CytRx Corporation – Pipeline Products Glance
CytRx Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CytRx Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CytRx Corporation – Drug Profiles
Bafetinib
Product Description
Mechanism of Action
R&D Progress
INNO-206
Product Description
Mechanism of Action
R&D Progress
Iroxanadine
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + Tamibarotene
Paclitaxel + Carboplatin + Tamibarotene
Product Description
Mechanism of Action
R&D Progress
Tamibarotene
Product Description
Mechanism of Action
R&D Progress
CytRx Corporation – Pipeline Analysis
CytRx Corporation – Pipeline Products by Therapeutic Class
CytRx Corporation – Pipeline Products By Target
CytRx Corporation – Pipeline Products by Route of Administration
CytRx Corporation – Pipeline Products By Mechanism of Action
CytRx Corporation – Recent Pipeline Updates
CytRx Corporation - Dormant Projects
CytRx Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Arimoclomol
INNO-105
CytRx Corporation – Company Statement
CytRx Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
CytRx Corporation, Recent Developments
CytRx Corporation- Press Release
May 07, 2012: CytRx To Present Complete Clinical Data From INNO-206 Phase Ib/II Trial At American Society of Clinical Oncology
Apr 26, 2012: CytRx Initiates Phase II Clinical Trial With INNO-206 In Pancreatic Cancer
Apr 12, 2012: CytRx Announces Issuance Of Key US Patent Covering INNO-206 Linker Technology
Mar 27, 2012: CytRx To Present Data On INNO-206 At AACR 2012 Annual Meeting
Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia
Nov 25, 2009: Cytrx Announces Plans To Initiate A Phase 2 Clinical Trial With Inno-206 In Patients With Advanced Soft Tissue Sarcomas
Sep 14, 2009: CytRx Corporation Announces Initiation Of A Dose Escalation Study
Jul 29, 2009: Preclinical Results Of CytRx Drug INNO-206 For Ovarian Tumor Shrinkage In Animal Trials.
Jun 29, 2009: CytRx Reports Favorable Progress Update For Its Pivotal Phase 2 Clinical Trial With Tamibarotene As A Third-line Treatment For Acute Promyelocytic Leukemia
Jun 17, 2009: CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity In Animal Trial For Multiple Myeloma
Financial Deals Landscape
CytRx Corporation, Deals Summary
CytRx Corporation, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
CytRx Acquires Clinical And Pharma Assets From Biorex
Partnerships
CytRx Enters Into Research Agreement With University Of Massachusetts
Licensing Agreements
CytRx Enters Into Licensing Agreement With The University of Massachusetts Medical School
CytRx Enters Into Licensing Agreement With Imperial College London
Equity Offering
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
CytRx Completes Private Placement Of $13.4 Million
CytRx Completes Private Placement Of $21.3 Million
CytRx Completes Private Placement Of $21.3 Million
CytRx Completes Private Placement Of $4 Million
Asset Transactions
Orphazyme Acquires Molecular Chaperone Assets From CytRx
CtyRx Sells Arimoclomo Royalty Interest To ALS Charitable Remainder Trust
Acquisition
ADVENTRX Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Acquires INNOVIVE Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
CytRx Corporation, Key Information
CytRx Corporation, Key Facts
CytRx Corporation – Pipeline by Indication, 2012
CytRx Corporation – Pipeline by Stage of Development, 2012
CytRx Corporation – Monotherapy Products in Pipeline, 2012
CytRx Corporation – Combination Treatment Modalities in Pipeline, 2012
CytRx Corporation – Phase II, 2012
CytRx Corporation – Phase I, 2012
CytRx Corporation – Pre-Clinical, 2012
CytRx Corporation – Pipeline By Therapeutic Class, 2012
CytRx Corporation - Pipeline By Target, 2012
CytRx Corporation – Pipeline By Route of Administration, 2012
CytRx Corporation – Pipeline Products By Mechanism of Action, 2012
CytRx Corporation – Recent Pipeline Updates, 2012
CytRx Corporation - Dormant Developmental Projects,2012
CytRx Corporation - Discontinued Pipeline Products, 2012
CytRx Corporation, Subsidiaries
CytRx Corporation, Deals Summary
CytRx Acquires Clinical And Pharma Assets From Biorex
CytRx Enters Into Research Agreement With University Of Massachusetts
CytRx Enters Into Licensing Agreement With The University of Massachusetts Medical School
CytRx Enters Into Licensing Agreement With Imperial College London
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
CytRx Completes Private Placement Of $13.4 Million
CytRx Completes Private Placement Of $21.3 Million
CytRx Completes Private Placement Of $21.3 Million
CytRx Completes Private Placement Of $4 Million
Orphazyme Acquires Molecular Chaperone Assets From CytRx
CtyRx Sells Arimoclomo Royalty Interest To ALS Charitable Remainder Trust
ADVENTRX Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Acquires INNOVIVE Pharma

List of Figures
CytRx Corporation – Pipeline by Indication, 2012
CytRx Corporation – Pipeline by Stage of Development, 2012
CytRx Corporation – Monotherapy Products in Pipeline, 2012
CytRx Corporation – Combination Treatment Modalities in Pipeline, 2012
CytRx Corporation – Pipeline By Therapeutic Class, 2012
CytRx Corporation - Pipeline By Target, 2012
CytRx Corporation – Pipeline By Route of Administration, 2012
CytRx Corporation - Pipeline Products By Mechanism of Action, 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Tuesday, May 21, 2013
4:15:41 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

CytRx Corporation - Product Pipeline Review - 2012

Web Address

http://www.researchandmarkets.com/reports/2141851

Office Code

OC8DIQSPURWVQT

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Tuesday, May 21, 2013
4:15:41 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

CytRx Corporation - Product Pipeline Review - 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)